Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px
Document › Details

DBV Technologies S.A.. (3/7/18). "Press Release: DBV Technologies to Present at the Barclays Global Healthcare Conference". Montrouge.

Organisations Organisation DBV Technologies S.A. (Euronext Paris: DBV + Nasdaq Global Select Market: DBVT)
  Organisation 2 Barclays (Group)
Products Product Barclays Global Healthcare Conference 2018 Miami
  Product 2 Viaskin® allergy treatment
Index term Index term DBV Technologies–Barclays: investor conference, 201803 supply service DBV Technologies presents at Barclays Global Healthcare Conference
Persons Person Mesa, Susanna (DBV Technologies 201507 VP Finance + US Investor Relations + Strategy)
  Person 2 Di Giorgio, Roberta (DBV Technologies 201709 Head Corp Communications)
     


Nasdaq Stock Market: DBVT) today announced that Susanna Mesa, Chief Business Officer, will present and host investor meetings at the Barclays Global Healthcare Conference on Wednesday, March 14, 2018, at 10:15 am EST in Miami, FL.

A live webcast of the presentation will be available on the Investors & Media section of the Company’s website: http://www.dbv-technologies.com/en/investor-relations. A replay will also be available approximately two hours after the event and will be accessible for 180 days.


About DBV Technologies

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbvtechnologies.com


DBV Investor Relations Contact
Sara Blum Sherman
Senior Director, Investor Relations & Strategy
+1 212-271-0740
sara.sherman@dbv-technologies.com

DBV Media Contact
Roberta Di Giorgio
Senior Director, Corporate Communications
+1 917-612-2861
roberta.digiorgio@dbv-technologies.com

   
Record changed: 2018-04-08

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px

More documents for DBV Technologies S.A. (Euronext Paris: DBV + Nasdaq Global Select Market: DBVT)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 600x60px




» top